Industry
Biotechnology
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Loading...
Open
0.80
Mkt cap
60M
Volume
325K
High
0.80
P/E Ratio
-3.13
52-wk high
1.53
Low
0.77
Div yield
N/A
52-wk low
0.77
Portfolio Pulse from
December 18, 2024 | 12:15 pm
Portfolio Pulse from
December 03, 2024 | 12:15 pm
Portfolio Pulse from
November 12, 2024 | 12:15 pm
Portfolio Pulse from
November 11, 2024 | 12:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 04, 2024 | 7:19 pm
Portfolio Pulse from Nabaparna Bhattacharya
October 04, 2024 | 11:08 am
Portfolio Pulse from Benzinga Newsdesk
September 19, 2024 | 3:32 pm
Portfolio Pulse from Benzinga Newsdesk
September 19, 2024 | 11:19 am
Portfolio Pulse from Benzinga Newsdesk
August 21, 2024 | 11:55 am
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 3:18 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.